Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

Targeting the stromal cell–derived factor 1α (SDF-1α)/C-X-C chemokine receptor type 4 (CXCR4) axis has been shown to be a promising therapeutic approach to overcome chemoresistance in acute myeloid leukemia (AML). We investigated the antileukemia efficacy of a novel peptidic CXCR4 antagonist, LY2510...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Cho, Byung-Sik, Zeng, Zhihong, Mu, Hong, Wang, Zhiqiang, McQueen, Teresa, Protopopova, Marina, Cortes, Jorge, Marszalek, Joseph R., Peng, Sheng-Bin, Ma, Wencai, Davis, R. Eric, Thornton, Donald E., Andreeff, Michael, Konopleva, Marina
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2015
Gaiak:
Myeloid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497963/
https://ncbi.nlm.nih.gov/pubmed/26031918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-628677
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak